Durability of treatment response on reachable workspace was observed among those who continued losmapimod throughout the 96-week period and those who switched from placebo. New long-term findings from the phase 2b ReDUX4 trial (NCT04003974) showed that treatment with losmapimod (Fulcrum…
Recording from the fist ever FSHD Nordic meeting, facilitated and organised by FSHD Society
I denna artikel tar författaren upp många viktiga frågor kring hur man ser på FSHD idag och att mycket av det är förlegat.
Här en Facebook grupp för Norge Vi i Norge med FSHD
Här finns en Facebook grupp för Sverige Vi med FSHD i Sverige
Sign up here to receive news about future trials and FSHD related information. We will not share your email adress with third parties.
FSHD Nordic is a private initiative to try raise awareness in the Nordic region and prepare the local FSHD community for future trials and accelerating getting therapeutics to the market once available.